ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BFRGW Bullfrog AI Holdings Inc

0.5398
0.0498 (10.16%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,140
Bid Price 0.4004
Ask Price 0.5399
News -
Company Name Stock Ticker Symbol Market Type
Bullfrog AI Holdings Inc BFRGW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
0.0498 10.16% 0.5398 16:00:03
Open Price Low Price High Price Close Price Prev Close
0.52 0.52 0.55 0.5398 0.49
Trades Volume VWAP Dollar Volume Avg Volume
16 4,140  0.5393444  2,233 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 100  0.52 USD

Bullfrog AI Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
17.61M 6.10M - 65k -5.36M -0.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Bullfrog AI

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BFRGW Message Board. Create One! See More Posts on BFRGW Message Board See More Message Board Posts

BFRGW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company¿s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. The Company¿s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targets Beta2-spectrin in the treatment of human diseases such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Your Recent History

Delayed Upgrade Clock